Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
====================================================================================================================================================================================

* Yoon-Koo Kang
* Martin Reck
* Paul Nghiem
* Yan Feng
* Gregory Plautz
* Hye Ryun Kim
* Taofeek K Owonikoko
* Narikazu Boku
* Li-Tzong Chen
* Ming Lei
* Han Chang
* Wen Hong Lin
* Amit Roy
* Akintunde Bello
* Jennifer Sheng